BackSun Pharma Advanced Research Company Limited Overview
Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited Return on Equity

Latest ROE for Sun Pharma Advanced Research Company Limited: 113.43% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

113.43%

Return on Equity

113.43%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Sun Pharma Advanced Research Company Limited (SPARC.NS) FAQ

Sun Pharma Advanced Research Company Limited (SPARC.NS) currently reports a ROE of 113.43%. That is above the sector sector average of 11.3%. Use the charts on this page to explore Sun Pharma Advanced Research Company Limited's ROE history and peer comparisons.

Sun Pharma Advanced Research Company Limited's ROE of 113.43% is higher than the its sector sector average of 11.3%. That is roughly 904.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sun Pharma Advanced Research Company Limited's current 113.43% should be judged against industry norms (sector average: 11.3%) and against SPARC.NS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 113.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.3%. From there, open related valuation or income-statement pages for Sun Pharma Advanced Research Company Limited, and consider following SPARC.NS for alerts when major investors trade the stock.